Plain-English translation of NCT05014464 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether ALK tyrosine kinase inhibitors—medications like , Alectinib, Brigatinib, and Lorlatinib—are effective for treating a rare type of advanced lung cancer (squamous cell carcinoma) that has a specific genetic mutation. Most research on these medications has focused on a different lung cancer type, so doctors want to understand how well this treatment works for your type of cancer. The study will also look at how the medication affects your survival and quality of life.
While these targeted medications have shown strong results in other lung cancer patients with this genetic change, very little research has been done in people with squamous cell carcinoma. This trial exists to fill that gap and help doctors decide whether genetic testing and this treatment should become standard for your type of lung cancer.
You likely qualify if…
You likely don't qualify if…
You will receive one of the targeted medications (, Alectinib, Brigatinib, or Lorlatinib) depending on which group you are assigned to and whether you have received prior treatments. The study will follow you for months to years, tracking how well the medication works, how you feel, and how your cancer responds through imaging and blood tests. You may be in one of three groups: people starting this medication for the first time, people switching to it as a second-line treatment, or people using it after other treatments have stopped working.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Hunan Province Tumor Hospital
Enrollment target
~90 participants
Started
November 2021
Primary completion
June 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in September 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Yongchang Zhang, MD
Hunan Cancer Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.